Bit Girl

$BTC ha perso il livello di $90.000 dopo aver visto le maggiori uscite settimanali dagli ETF Bitcoin da novembre. Questo non è stato un evento di poco conto. Quando gli ETF vedono forti uscite, significa che grandi investitori stanno riducendo l'esposizione. Quella pressione di vendita ha spinto Bitcoin al di sotto di un importante livello psicologico e tecnico.

Dopo questo flush, Bitcoin si è stabilizzato. Ma stabilizzazione non significa forza. In questo momento, Bitcoin si sta muovendo all'interno di un intervallo. Non sta seguendo una tendenza al rialzo e non sta nemmeno scendendo completamente. Questo è un segno classico di incertezza.

Pain management is one of the most complicated challenges in modern medicine. Millions of people live with chronic pain every day, yet many of the available treatments either don’t work well enough or come with serious risks. Over the past two decades, the opioid crisis made this painfully clear. When effective alternatives were missing, healthcare systems relied heavily on opioid medications — and the consequences were devastating.
Today, the search for safe, effective, non-opioid pain treatments has become one of the most important goals in medical research.
One area where this need is especially urgent is neuropathic pain.
Understanding Neuropathic Pain
Neuropathic pain occurs when the nervous system itself is damaged or malfunctioning. Instead of simply responding to injury, the nerves begin sending abnormal pain signals to the brain. Patients often describe the sensation as:
Burning painElectric-shock sensationsNumbness or tinglingExtreme sensitivity to touch
Unlike temporary pain from an injury, neuropathic pain can persist for months or even years, significantly affecting quality of life.
One of the most difficult forms of neuropathic pain occurs in cancer patients receiving chemotherapy.

The Hidden Burden of Chemotherapy-Induced Neuropathy
Chemotherapy saves lives, but it can also damage peripheral nerves. This condition is known as chemotherapy-induced peripheral neuropathy (CIPN).
Patients experiencing CIPN often report:
Persistent nerve painLoss of sensation in hands and feetDifficulty walking or performing daily tasksLong-lasting burning or stabbing sensations
For many people, these symptoms continue even after cancer treatment ends. Unfortunately, current treatment options for CIPN remain limited, and many patients struggle to find effective relief.
This is why new therapeutic research in this area is so important.

A New Direction: Ketamir-2
Recent progress in experimental therapies is beginning to explore alternatives that target nerve pain more safely. One such candidate is Ketamir-2, a drug currently being developed by Mira Pharmaceuticals.
According to early clinical trial updates, the Phase 1 trial of Ketamir-2 has been completed successfully, with encouraging safety signals:
No serious adverse events reportedNo ketamine-like central nervous system side effects observed
These results are particularly important because many drugs that target similar pathways — including ketamine — can cause significant neurological side effects. Avoiding these issues while still addressing pain is a key challenge in drug development.
Following the positive safety data from Phase 1, the therapy is now advancing into Phase 2a clinical trials, where researchers will begin evaluating its effectiveness in treating chemotherapy-induced peripheral neuropathy.

Why This Research Matters
The development of safer pain treatments is about far more than pharmaceutical innovation. It represents a broader shift in how medicine approaches pain management.
For decades, the absence of effective alternatives forced physicians to rely heavily on opioids. While opioids can reduce pain, they also carry risks including dependency, overdose, and long-term health complications.
The opioid crisis demonstrated what happens when medical systems lack safer options.
That experience changed how researchers, regulators, and healthcare providers think about pain therapy. Today, the focus is increasingly on non-opioid solutions that target the underlying biology of pain without creating new risks.
If successful, therapies like Ketamir-2 could help fill a critical gap for patients who currently have very few options.

The Long Road of Drug Development
It is important to remember that drug development is a long and careful process. Moving from Phase 1 safety trials into Phase 2 and later stages requires extensive research, testing, and regulatory evaluation.
However, every step forward brings scientists closer to understanding how new treatments might help patients.
For individuals suffering from chronic neuropathic pain — especially those already battling cancer — even incremental progress can make a meaningful difference.
Looking Ahead
Pain medicine is entering a new era. Researchers are exploring innovative approaches that focus on targeted neural pathways, safer pharmacology, and non-addictive treatments.
While many challenges remain, developments like the progress of Ketamir-2 highlight the growing momentum behind this effort.
For millions of people living with chronic nerve pain, the future of pain treatment may depend on exactly this kind of scientific innovation.

#Mira @mira_network

When I first read that Fabric Foundation integrated the Base chain for transaction settlement, it initially looked like a routine infrastructure decision. But the more I thought about it, the more it seemed like a strategic move for how decentralized robotics ecosystems might actually function.
Fabric’s vision involves robots and autonomous systems interacting within digital economies. If machines are expected to coordinate tasks, verify activity, and exchange resources on-chain, the blockchain layer supporting those interactions must handle frequent and inexpensive transactions.
This is where Base becomes relevant.
Autonomous systems behave differently from human users. A person might perform a handful of blockchain transactions each day. A machine network, however, could generate continuous interactions such as registering task completion, verifying machine activity, coordinating services between devices, or settling payments for resources.
If thousands of machines are operating simultaneously, the transaction layer quickly becomes critical infrastructure.
From that perspective, Fabric exploring an Ethereum Layer-2 environment like Base makes practical sense.
Base provides lower transaction costs and higher throughput while maintaining compatibility with Ethereum’s broader ecosystem. That combination allows Fabric to rely on a scalable settlement environment while focusing its development on robotics coordination and automation networks.
What I find interesting about the emerging Decentralized AI and Robotics (DeAI) landscape is that different projects are building different pieces of the stack. Some focus on decentralized compute for AI models, while others develop frameworks for autonomous agents.
Fabric appears to be addressing another layer: how robotics systems interact with decentralized infrastructure.
Integrating with Base suggests a modular strategy. Instead of building its own settlement layer, Fabric can leverage existing blockchain scalability while concentrating on its robotics coordination architecture.
From my perspective, infrastructure decisions like this often shape how ecosystems grow later. If automation networks eventually involve large numbers of machines interacting with digital systems, the blockchain supporting those interactions must scale without friction.
Fabric’s adoption of Base may therefore represent more than a technical integration. It could be early preparation for an environment where autonomous machines interact with blockchain networks at scale.
If robotics networks eventually operate on blockchain infrastructure, which factor will become more important for automation ecosystems:
AI capability or transaction infrastructure?

#ROBO @Fabric Foundation $ROBO

$MIRA

Quando ho iniziato a esaminare come i sistemi di intelligenza artificiale vengono effettivamente utilizzati in ambienti reali, una cosa continuava a risaltare per me: gli esseri umani li supervisionano ancora costantemente.
Anche i modelli di intelligenza artificiale più avanzati raramente operano completamente da soli. Generano output, ma quei risultati di solito devono essere controllati, corretti o approvati dalle persone prima che chiunque possa fidarsi completamente di essi.
Più leggevo a riguardo, più sembrava che uno dei costi nascosti più grandi dell'intelligenza artificiale non fosse costruire i modelli stessi — è il continuo bisogno di supervisione umana.

$ROBO

Quando ho iniziato a leggere per la prima volta riguardo a Fabric Foundation, la maggior parte delle spiegazioni si concentrava sui robot e sull'automazione. A prima vista sembrava un altro tentativo di collegare la robotica con l'infrastruttura blockchain.
Ma più guardavo all'architettura, più sembrava che Fabric stesse effettivamente affrontando un problema più profondo: come verifichiamo l'attività delle macchine nei sistemi decentralizzati.
Negli ambienti di automazione tradizionali, la verifica è semplice perché il sistema è centralizzato. Un'azienda possiede i robot, controlla il software e registra i risultati. Se una macchina completa un compito, la piattaforma semplicemente conferma che è successo.